Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

E, Ferrannini; V, Fonseca; B, Zinman; D, Matthews; B, Ahrén; S, Byiers; Q, Shao; S, Dejager

doi:10.1111/j.1463-1326.2008.00994.x

Public

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Shared by NobleBlocks on Feb 1, 2009 • 12:00 AM UTC

Authors:

Ferrannini E

Fonseca V

Zinman B

Abstract

Aim To examine the efficacy and safety of vildagliptin vs. glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus in a 52-week interim analysis of a large, randomized, double-blind, multicentre study. The primary objective was to demonstrate non-inferiority of vildaglip...

Discussions